A Phase I/II Study of AST-001 in Subjects With Advanced Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1/PHASE2

Total Enrollment

180 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-07-07

Study Completion Date

2027-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A first-in-human open-label, Phase I/II study to evaluate the safety, tolerability, MTD/RP2D, PK, and preliminary efficacy of AST-001 administered as a single agent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors

NCT06239155

Advanced Solid Tumors Hepatocellular Carcinoma

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of ASKC202 With or Without ASK120067

NCT05306132

Advanced Solid Tumor

RECRUITING PHASE1

Study of AS1411 in Advanced Solid Tumours

NCT00881244

Advanced Solid Tumors

COMPLETED PHASE1

Study of ASTX029 in Subjects With Advanced Solid Tumors

NCT03520075

Solid Tumor, Adult

COMPLETED PHASE1/PHASE2

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ASD141

NCT06235437

Metastatic Solid Tumor

RECRUITING PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Solid Tumor Pancreatic Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose escalation phase

AST-001 (5.0 mg/m\^2 to 40.0 mg/m\^2) will be administered by IV infusion on Days 1, 8 and 15 of each 28-day cycle to determine the MTD and RP2D with a BOIN design.

Group Type EXPERIMENTAL

AST-001

Intervention Type DRUG

liquid formulation for Intravenous infusion

phase II pancreatic cancer

AST-001 (RP2D) will be administered by IV infusion on Days 1, 8 and 15 of each 28-day cycle

Group Type EXPERIMENTAL

AST-001

Intervention Type DRUG

liquid formulation for Intravenous infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AST-001

liquid formulation for Intravenous infusion

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient has ability to understand the risks of the study and is willing to comply with the protocol and has signed a written informed consent.
2. Aged 18-70 years (inclusive), males and females.
3. Histologically or cytologically confirmed solid malignancy that is metastatic or unresectable and for which standard curative do not exist or are no longer effective.
4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
5. Expected life expectancy ≥ 12 weeks
6. Recovered from toxicities of prior therapy to Grade 0 or 1
7. An adequate renal, liver and bone marrow function.

1. Patient has ability to understand the risks of the study and is willing to comply with the protocol and has signed a written informed consent.
2. Aged 18-70 years (inclusive), males and females.
3. Histologically or cytologically confirmed pancreatic cancer that is unresectable or cannot be controlled by local treatment and for which standard curative do not exist or are no longer effective.
4. At least one measurable lesion that meets RECIST 1.1 criteria.
5. Can provide pathological wax blocks or sections (including archived pathological wax blocks or sections) for AKR1C3 expression analysis and be confirmed that AKR1C3 expression is strongly positive.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
7. Expected life expectancy ≥ 12 weeks
8. Recovered from toxicities of prior therapy to Grade 0 or 1
9. An adequate renal, liver and bone marrow function.

Exclusion Criteria

1. History of another primary malignancy within 2 years prior to Day 1, except for adequately treated basaloma, in situ cancer, or other cancers whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the current study.
2. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1.
3. Treatment with radiation therapy, chemotherapy, biotherapy, targeted therapies or hormones within 4 weeks prior to Day 1.
4. Receiving investigational therapy within 4 weeks prior to Day 1.
5. Concomitant use of repaglinide, medium/strong CYP2C8/CYP2B6/ CYP2C9 inhibitors/inducers.
6. Pleural effusion or ascites which need to be drained every other week or more frequently.
7. HBV infection and HBV-DNA ≥ 2,000 IU/mL
8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
9. History of human immunodeficiency virus (HIV) infection or syphilis infection.
10. History of cardiac disease fits any of the following conditions：

1. NYHA III or IV CHF；
2. QTcF : male \> 450ms，female \> 470ms；
3. Myocardial infarction, bypass surgery, stent surgery within 6 months prior to Day 1；
4. Other cardiac disease that the investigator judged unsuitable for inclusion.
11. Females who are pregnant or breast-feeding
12. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
13. Previously allergic to ethanol, polyoxyethylene (35) castor oil, N, N-dimethylacetamide.
14. Unwillingness or inability to comply with the study protocol for any reason

* phase II: pancreatic cancer

1. History of another primary malignancy within 2 years prior to Day 1, except for adequately treated basaloma, in situ cancer, or other cancers whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the current study.
2. Major surgery, other than diagnostic surgery, within 4 weeks prior to Day 1.
3. Treatment with radiation therapy, chemotherapy, biotherapy, targeted therapies or hormones within 4 weeks prior to Day 1.
4. Receiving investigational therapy within 4 weeks prior to Day 1.
5. Concomitant use of repaglinide, medium/strong CYP2C8/CYP2B6/ CYP2C9 inhibitors/inducers.
6. Pleural effusion or ascites which need to be drained every other week or more frequently.
7. HBV infection and HBV-DNA ≥ 2,000 IU/mL
8. Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy.
9. History of human immunodeficiency virus (HIV) infection or syphilis infection.
10. History of cardiac disease fits any of the following conditions：

1. NYHA III or IV CHF；
2. QTcF : male \> 450ms，female \> 470ms；
3. Myocardial infarction, bypass surgery, stent surgery within 6 months prior to Day 1；
4. Other cardiac disease that the investigator judged unsuitable for inclusion.
11. Females who are pregnant or breast-feeding
12. Concomitant disease or condition that could interfere with the conduct of the study, or that would, in the opinion of the investigator, pose an unacceptable risk to the subject in this study
13. Previously allergic to ethanol, polyoxyethylene (35) castor oil, N, N-dimethylacetamide.
14. Unwillingness or inability to comply with the study protocol for any reason

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No